BREYANZI

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, Lithuania, Poland.

Active ingredients

The drug BREYANZI contains one active pharmaceutical ingredient (API):

1	Lisocabtagene maraleucel UNII 7K2YOJ14X0 - LISOCABTAGENE MARALEUCEL
	Lisocabtagene maraleucel is a CD19-directed genetically modified autologous cellular immunotherapy administered as a defined composition to reduce variability in CD8+ and CD4+ T-cell dose. CAR binding to CD19 expressed on the cell surface of tumour and normal B cells induces activation and proliferation of CAR T cells, release of pro-inflammatory cytokines, and cytotoxic killing of target cells.
	Read more about Lisocabtagene maraleucel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BREYANZI Dispersion for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XL08		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1880737
LT	Valstybinė vaistų kontrolės tarnyba	1094513
PL	Rejestru Produktów Leczniczych	100468788
US	FDA, National Drug Code	73153-900, 73153-901, 73153-902